N-芴甲氧羰基-L-别苏氨酸叔丁醚 | 201481-37-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N-芴甲氧羰基-L-别苏氨酸叔丁醚
• 中文别名: 红曲玉红胺
• 英文名称: (2S,3S)-3-(tert-butoxy)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)butanoic acid
• 英文别名: Fmoc-allo-Thr(tBu)-OH；(2S,3S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid
• CAS: 201481-37-0
• 化学式: C₂₃H₂₇NO₅
• 分子量: 397.471
• InChiKey: LZOLWEQBVPVDPR-XOBRGWDASA-N

物化性质

• 沸点：
  581.7±50.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  保存方法：在2至-8°C下存放。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-Allo-Thr(tBu)-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-Allo-Thr(tBu)-OH
CAS number: 201481-37-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C23H27NO5
Molecular weight: 397.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

O-(叔丁基)-N-Fmoc-L-异苏氨酸是一种苏氨酸衍生物[1]。

反应信息

• 作为反应物：
  描述：

  N-芴甲氧羰基-L-别苏氨酸叔丁醚 在 二乙胺 、 N,N'-二环己基碳二亚胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 53.67h， 生成
  参考文献：
  名称：

  双环Theonellamide骨架的组装进展

  摘要：

  的正交保护的τ-histidinoalanine残余物通过旋光纯的Boc-的区域选择性烷基化，合成升与亲电子从的Fmoc-衍生的磺酰胺酯-His-OTCE（TCE =三氯乙基）d -Ser-OBn的 目的是合成一种非天然的theonellamide，并调用其他10个氨基酸的易于获得的变体。在溶液中合成了与“ theonellamide X”的东环和西环相对应的肽片段。每个环都是独立形成的，可深入了解保护基团的限制，副反应以及接近双环系统形成的最佳事件顺序。最终，制备了十一肽，形成了东环。第十二氨基酸，升制备了-α-氨基己二酸构件，并报道了其与十一肽的连接的初步研究。

  DOI：

  10.1016/j.tet.2020.131127
• 作为产物：
  描述：

  O-叔丁基-L-别苏氨酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 18.0h， 生成 N-芴甲氧羰基-L-别苏氨酸叔丁醚
  参考文献：
  名称：

  真菌双加氧酶AsqJ是混杂的且是双峰的：喹诺酮类与喹唑啉酮类的底物定向形成

  摘要：

  先前的研究表明，Fe II /α-酮戊二酸依赖性双加氧酶AsqJ诱导构巢曲霉在viridicatin生物合成中的骨架重排，从苯并[1,4]二氮杂-2,5-二酮底物生成喹诺酮骨架。我们报告说，仅通过改变苯并二氮杂二酮底物中的取代基，AsqJ即可催化另外的，完全不同的反应。通过底物筛选，功能探针的应用和计算分析来建立这种新机制。AsqJ消费税H 2由合适的苯并[1,4]二氮杂-2-5,5-二酮底物的杂环结构生成CO，生成喹唑啉酮。这种新颖的AsqJ催化途径由复杂底物中的单个取代基控制。AsqJ的这种独特的底物定向反应性可实现喹诺酮或喹唑啉酮的靶向生物催化生成，喹诺酮或喹唑啉酮是两种具有特殊生物医学相关性的生物碱框架。

  DOI：

  10.1002/anie.202017086

文献信息

• A facile synthesis and crystallographic analysis of N-protected β-amino alcohols and short peptaibols
  作者：Sandip V. Jadhav、Anupam Bandyopadhyay、Sushil N. Benke、Sachitanand M. Mali、Hosahudya N. Gopi

  DOI：10.1039/c0ob01226b

  日期：——

  for the synthesis of N-protected β-amino alcohols and peptaibols using N-hydroxysuccinimide active esters is described. Using this method, dipeptide, tripeptide and pentapeptide alcohols were isolated in high yields. The conformations in crystals of β-amino alcohol, dipeptide and tripeptide alcohols were analysed, with a well-defined type III β-turn being observed in the tripeptide alcohol crystals

  一种简便，高效且无外消旋的方法，使用该方法合成N保护的β-氨基醇和肽醇N-羟基琥珀酰亚胺描述了活性酯。使用这种方法，可以高产率分离出二肽，三肽和五肽醇。分析了β-氨基醇，二肽和三肽醇的晶体构象，在三肽醇晶体中观察到了明确定义的III型β角。发现该方法与Fmoc-，Boc-和其他侧链保护基相容。
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• Cysteine protease inhibitors
  申请人：——

  公开号：US20030186962A1

  公开（公告）日：2003-10-02

  of the formula (IV): 1 where: R1=R′C(O), R′SO2, R′=a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or R′=a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and/or c) and which may optionally bear one or two further substituents selected from group b); R4=H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl; R3=C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl, Ar; R5=C1-7-alkyl, halogen, Ar-C1-7-alkyl, C1-3-alkyl-CONR3R4 or a bulky amine R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO2-R ix , C1-3-alkyl-C(O)—NHR ix or CH 2 XAr q is 0 or 1 have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.

  公式（IV）的翻译如下： 其中： R1=R′C(O)，R′SO2， R′=含有0-4个来自S、O和N的杂原子的8-12元环系统，可以选择饱和或不饱和的双环，可选地取代最多四个从下面的a)、b)和c)组中独立选择的取代基；或 R′=含有0-3个来自S、O和N的杂原子的5-7元环，该单环至少带有从a)组和/或c)组中选择的一个取代基，并且可选地带有从b)组中选择的一个或两个进一步的取代基； R4=H，C1-7-烷基，Ar-C1-7-烷基，Ar，C3-7-环烷基；C2-7-烯基； R3=C1-7-烷基，C2-C7烯基，C2-C7烯基，C3-7-环烷基，Ar-C1-7-烷基，Ar； R5=C1-7-烷基，卤素，Ar-C1-7-烷基，C1-3-烷基-CONR3R4或体积庞大的胺 R6为H，C1-7-烷基，Ar-C1-7-烷基，C1-3-烷基-SO2-R ix ，C1-3-烷基-C(O)—NHR ix 或CH 2 XAr q为0或1 具有作为半胱氨酸蛋白酶抑制剂的实用性，例如卡特普辛K和疟原虫蛋白酶。
• LYSOBACTIN AMIDES
  申请人：VON NUSSBAUM Franz

  公开号：US20090203582A1

  公开（公告）日：2009-08-13

  The invention relates to lysobactin amides and methods for their preparation, as well as their use for manufacturing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.

  这项发明涉及赖氨酸胞素酰胺及其制备方法，以及它们用于制造治疗和/或预防疾病，特别是细菌感染性疾病的药物的用途。
• Structure-activity relationships of tubulysin analogues
  作者：Joel R. Courter、Joseph Z. Hamilton、Nathaniel R. Hendrick、Margo Zaval、Andrew B. Waight、Robert P. Lyon、Peter D. Senter、Scott C. Jeffrey、Patrick J. Burke

  DOI：10.1016/j.bmcl.2020.127241

  日期：2020.7

  the multi-drug resistant (MDR) phenotype. These drugs possess a C-11 acetate known to be hydrolytically unstable in plasma, and loss of the acetate significantly attenuates cytotoxicity. Structure-activity relationship studies were undertaken to identify stable C-11 tubulysin analogues that maintain affinity for tubulin and potent cytotoxicity. After identifying several C-11 alkoxy analogues that possess

  微管溶素是一种新兴的抗体-药物偶联物（ADC）有效负载，可对显示多药耐药（MDR）表型的细胞保持有效的抗增殖活性。这些药物具有已知在血浆中水解不稳定的C-11乙酸盐，并且乙酸盐的损失会大大减弱细胞毒性。进行了结构-活性关系研究，以鉴定稳定的C-11微管溶素类似物，这些类似物保持对微管蛋白的亲和力和有效的细胞毒性。在鉴定出几种具有与微管溶蛋白M相当的生物活性并具有明显改善的血浆稳定性的C-11烷氧基类似物后，Ile残基和N的其他类似物-末端位置被合成。这些研究表明，微管蛋白溶酶的微管蛋白结合位点内的微小变化可深刻改变这种化学型的活性，特别是针对MDR阳性细胞类型。